PMID-39082657 – Dissolving Microneedle Patch Acetyl Octapeptide-3 Anti-Wrinkle
Kim H, et al. "Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities." Journal of Cosmetic Dermatology, 2024;23(9):2913-2923.
Quick Reference
| Property | Value |
|---|---|
| PMID | 39082657 |
| DOI | 10.1111/jocd.16463 |
| Year | 2024 |
| Journal | Journal of Cosmetic Dermatology |
| Study Type | RCT (split-face, placebo-controlled) |
| Evidence Level | II |
| Sample | 24 healthy human subjects |
| Peptide(s) Studied | SNAP-8 |
Key Findings
- Developed a dual anti-wrinkle microneedle patch (DA-MNP) using droplet extension technology containing acetyl octapeptide-3 (SNAP-8), L-ascorbic acid 2-glucoside, and sodium cyclic lysophosphatidic acid in a hyaluronic acid backbone
- DA-MNP had sufficient mechanical strength to puncture the stratum corneum, overcoming the major delivery barrier for hydrophilic peptides
- Split-face clinical trial demonstrated effective eye wrinkle improvement versus placebo
- Reduced trans-epidermal water loss (TEWL), indicating improved skin barrier function
- Enhanced skin elasticity and lifting effects observed
- No adverse effects reported compared to placebo patches
- Results demonstrate that microneedle delivery can overcome the stratum corneum penetration limitation of topical SNAP-8
Study Design
Split-face, placebo-controlled clinical study. 24 healthy subjects received DA-MNP on one periorbital area and placebo MNP on the contralateral side, applied overnight. Assessments at baseline and after 28 days of use. Endpoints included wrinkle depth (skin topography), TEWL, skin elasticity, lifting effect, and adverse events.
Limitations
- Small sample size (n=24)
- 28-day duration; long-term efficacy and safety unknown
- Combination product (SNAP-8 + vitamin C derivative + lysophosphatidic acid); cannot attribute effects solely to SNAP-8
- Microneedle delivery format differs from typical topical application — results may not translate to conventional serums/creams
- Manufacturer-involved study
Clinical Relevance
This study demonstrates that the key limitation of topical SNAP-8 — poor penetration through the stratum corneum — can be overcome with microneedle delivery technology. The positive clinical results in a controlled trial provide Level II evidence for SNAP-8 anti-wrinkle efficacy, though in a combination product. For practitioners using SNAP-8 topically, this highlights the importance of formulation and delivery strategy for achieving meaningful clinical outcomes.
Related
#research #RCT #SNAP-8 #cosmetic #evidence-level-II